期刊
BRAIN RESEARCH
卷 881, 期 2, 页码 204-207出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/S0006-8993(00)02742-6
关键词
corticotropin releasing hormone; corticotropin releasing hormone antagonist; alpha-helical CRH9-41; antalarmin; blood pressure; rat
资金
- NIDA NIH HHS [DA 000254] Funding Source: Medline
Central administration of CRH results in endocrinological. cardiovascular, and behavioral effects that suggest stress or anxiety. Among these is a marked presser response. Parenteral administration of CRH, however, results in hypotension. We used parenteral administration of antalarmin, a novel, small molecule CRH1 receptor antagonist, and alpha -helical CRH9-41, a peptidic CRHR1/CRHR2 antagonist to attempt to determine the receptor mechanisms through which CRH is acting in both of these situations. Our results suggest that the hypertension produced by central CRH administration is mediated through central CRHR1 receptors, whereas the hypertension produced by parenteral CRH administration is mediated through peripheral CRHR2 receptors. (C) 2000 Elsevier Science B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据